Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 7/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190492 | 0.84 | KDM4E (0.37) | ALOX15MAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL23979557 | 0.83 | SLC6A2 (0.34) | GPR139ALOX15ALDH1A1GLALMNA | |
| SCHEMBL19132013 | 0.75 | KDM4E (0.38) | GPR139MAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL20314838 | 0.74 | SMN1; SMN2 (0.33) | MAPTRAB9ANPC1L3MBTL1KDM4E | |
| SCHEMBL19131915 | 0.71 | TBXAS1 (0.49) | PTGS1 | |
| SCHEMBL24371181 | 0.71 | SMN1; SMN2 (0.39) | ALOX15MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL12550247 | 0.70 | ESR1 (0.40) | HPGDFAAHCA1CA2LMNA | |
| SCHEMBL25482778 | 0.70 | MAOB (0.37) | GPR139KDM4EALDH1A1GAALMNA | |
| SCHEMBL24410533 | 0.70 | ESR1 (0.33) | LMNA | |
| SCHEMBL732708 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023020521-A1 | PYRIDINE FUSED PYRIMIDINE DERIVATIVES AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023020519-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | GPR139 3645/4885ALOX15 3316/4885MAPT 3644/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GPR139 2927/4885ALOX15 393/4885MAPT 2020/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GPR139 4492/4885ALOX15 4836/4885MAPT 1162/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | GPR139 3645/4885ALOX15 3316/4885MAPT 3644/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | GPR139 314/4885ALOX15 3070/4885MAPT 4710/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GPR139 3248/4885ALOX15 1008/4885MAPT 3695/4885 |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | FNTB, PGLS, EP300 | GPR139 1941/4885ALOX15 1418/4885MAPT 1082/4885 |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | GPR139 3594/4885ALOX15 3727/4885MAPT 4499/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GPR139 3248/4885ALOX15 1008/4885MAPT 3695/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GPR139 3248/4885ALOX15 1008/4885MAPT 3695/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | GPR139 1039/4885ALOX15 3410/4885MAPT 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.